BiotechTube

Latiglutenase

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Celiac Disease

Conditions

Celiac Disease

Trial Timeline

Nov 1, 2019 → Oct 31, 2023

NCT ID
NCT04243551

About Latiglutenase

Latiglutenase is a phase 2 stage product being developed by Allergy Therapeutics for Celiac Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT04243551. Target conditions include Celiac Disease.

Hype Score Breakdown

Clinical
12
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04243551Phase 2Terminated

Competing Products

17 competing products in Celiac Disease

See all competitors
ProductCompanyStageHype Score
DONQ52 + PlaceboChugai PharmaceuticalPhase 1
29
Placebo DONQ52 + DONQ52Chugai PharmaceuticalPhase 2
42
Placebo + RO5459072RochePhase 1
29
CCX282-B + PlaceboAmgenPhase 2
35
AMG 714 + PlaceboAmgenPhase 2
35
AMG 714 + PlaceboAmgenPhase 2
35
AMG 714AmgenPre-clinical
26
KAN-101 + PlaceboPfizerPhase 2
35
Cohort 1 in Part A + Cohort 2 in Part A + Group 2 in Part B and Part C + Group 3 in Part B and Part C + Group 4 in Part B and Part CPfizerPhase 1/2
24
Ritlecitinib + PlaceboPfizerPhase 2
42
PRV-015SanofiPhase 2
35
TIMP-GLIATakeda PharmaceuticalPhase 1
29
TIMP-GLIA + PlaceboTakeda PharmaceuticalPhase 2
35
PTG-100 + PlaceboProtagonist TherapeuticsPhase 1
26
Rifaximin + PlaceboBausch HealthPre-clinical
20
BL-7010 + PlaceboBioLineRxPhase 1/2
22
VTP-1000Barinthus BiotherapeuticsPhase 1
26